Skip to content

Concerto — Codetta Bio

Codetta Bio's Concerto positions as a multimodal biomarker platform measuring DNA, RNA, and protein from the same sample — pitched as a single-instrument alternative to stacking separate genomics, transcriptomics, and proteomics workflows.

At a glance

  • Vendor / launch date / availability: Codetta Bio; profiled at AGBT 2026 (Marco Island, Feb 22–25); commercially available per GEN AGBT 2026 recap.
  • Chemistry / modality: Multimodal biomarker platform — co-measurement of DNA, RNA, and protein analytes from a single workflow per GEN AGBT 2026 recap.
  • Throughput (PR): TBD — public AGBT coverage did not enumerate samples/run or analytes/sample for Concerto.
  • Read length: n/a (Concerto is a biomarker-readout instrument, not a sequencer; outputs are analyte counts/signals, not reads).
  • Accuracy (PR): TBD — no LoD / sensitivity / specificity figures in the public AGBT 2026 trade-press coverage indexed in program-notes.
  • List price / cost-per-sample: TBD — no public list price or per-sample reagent cost surfaced in AGBT 2026 coverage.

Source caveat: AGBT 2026 public coverage of Codetta Bio is sparse — the GEN recap names Concerto in the multi-vendor sweep but does not break out chemistry or specs. Most quantitative fields here are flagged TBD pending a dedicated Codetta press release or third-party benchmark. (vendor PR — no independent benchmark) applies to all spec claims below.

What's new vs prior generation

Codetta Bio is a newer entrant in the multimodal-biomarker category; Concerto is its AGBT 2026 commercial entry. The strategic differentiation versus single-cell multiomics workflows (10x Chromium multiome, BD Rhapsody, Parse Biosciences) is bulk multimodal measurement on the same physical sample without the dissociation/microfluidic overhead of single-cell methods, optimized for biomarker discovery and clinical-trial sample throughput rather than single-cell resolution.

Headline benchmarks

TBD — no public benchmarks indexed at time of writing. Backfill when Codetta posts a methods paper, application note, or independent third-party comparison.

Reception / competitive context

Concerto sits at the intersection of two AGBT 2026 narratives: (a) the multiomics-from-one-sample push that 10x's Atera/Xenium-RNA+Protein and Bruker's CosMx + Singular's G4X are all pushing on the spatial side, and (b) the biomarker / clinical-trial-readout segment that traditionally relies on stacking ELISA + qPCR + NGS panels. For AACR-axis applications (clinical-trial biomarker panels, drug-response signatures), Concerto's pitch competes with single-cell multiome (Rhapsody, 10x Chromium multiome) on multimodal coverage and with Olink / SomaScan + RNA-seq stacks on workflow consolidation.

  • Single-cell multiomics competitors at AGBT 2026: Waters Rhapsody refresh, 10x Genomics Atera + Xenium RNA+Protein.
  • AACR axis — biomarker / clinical trials: multimodal biomarker platforms feed clinical-trial pharmacodynamic readouts and pretreatment biomarker stratification; expect Concerto application notes to surface in AACR 2027 (too new for AACR 2026 data posters).
  • Bioconductor downstream: multimodal biomarker output naturally lands in MultiAssayExperiment for harmonized multi-modality storage.
  • AGBT 2026 lineage: Codetta Bio is profiled alongside Cellanome, Syndex Bio, and Volta Labs in the GEN AGBT 2026 recap as part of the "emerging platforms" sweep.

Sources

Open items: locate a primary Codetta Bio press release or product page enumerating Concerto's analyte panel, throughput, and pricing. Backfill spec table and benchmarks lines once a primary source is reachable.